Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0SACUI
ADC Name
BB-1705
Synonyms
BB-1705; BB 1705; BB1705
   Click to Show/Hide
Organization
Baili Sikang Biomedicine (Hangzhou) Co., Ltd.
Drug Status
Phase 1/2
Indication
In total 1 Indication(s)
Solid tumor
Phase 2
Clinical Trial
Drug-to-Antibody Ratio
2
Structure
Antibody Name
Undisclosed
Antigen Name
Epidermal growth factor receptor (EGFR)
  Antigen Info 
Payload Name
Eribulin
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Mc-PEG2-Val-Cit-PABC
  Linker Info 
Conjugate Type
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05217693
Phase 1/2
A phase 1/2 first-in-human, open label, multicenter, dose escalation and cohort expansion study to investigate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of BB-1705 in patients with locally advanced/metastatic solid tumors.

   Click to Show/Hide
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05217693  Clinical Status Phase 1/2
Clinical Description A phase 1/2 first-in-human, open label, multicenter, dose escalation and cohort expansion study to investigate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of BB-1705 in patients with locally advanced/metastatic solid tumors.
References
Ref 1 A Phase I/II First-in-human, Open Label, Multicenter, Dose Escalation and Cohort Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of BB-1705 in Patients With Locally Advanced/Metastatic Solid Tumors, NCT05217693